88971-33-9Relevant academic research and scientific papers
DENDRIMER FORMULATIONS
-
Page/Page column 62, (2020/03/05)
Disclosed are pharmaceutical compositions comprising a lyophilized compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, and methods of using the same for treating cancer.
THERAPEUTIC DENDRIMER
-
Page/Page column 58, (2020/02/14)
Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a cabazitazel residue covalently attached to a diglycolyl linker group, and second
CONJUGATES FOR USE IN METHODS OF TREATING CANCER
-
Page/Page column 55; 58, (2020/03/05)
Disclosed are methods of treating cancer in a subject, comprising subcutaneously administering to the subject an effective amount of a dendrimer of formula (I): (I) and pharmaceutically acceptable salts thereof.
THERAPEUTIC DENDRIMER
-
Page/Page column 79, (2020/06/10)
Provided herein are dendrimers comprising: a core unit, five generations of building units which are lysine residues or analogues thereof, first terminal groups comprising a residue of a camptothecin active covalently attached to a diglycolyl linker group
THERAPEUTIC DENDRIMERS
-
Page/Page column 78, (2018/09/19)
Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.
